PCM
KNSA icon

Prelude Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Prelude Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,594
Closed -$221K – 1394
2026
Q1 		$221K Sell
4,594
-2,476
-35% -$110K 0.02% 863
2025
Q4 		$292K Buy
+7,070
New +$284K 0.02% 807
2019
Q3 		– Sell
-425
Closed -$6K – 1888
2019
Q2 		$6K Buy
+425
New +$6.59K ﹤0.01% 1499

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Prelude Capital Management's KNSA Position: Q2 2026 in Review

Prelude Capital Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 4,594 shares — an estimated $221K sold.

Prelude Capital Management first reported a position in KNSA in Q2 2019 and held it in 3 quarters. The position peaked at $292K in Q4 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Prelude Capital Management reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 4,594 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $221K.
  • Prelude Capital Management first reported a position in Kiniksa Pharmaceuticals in Q2 2019 and held it in 3 quarters.
  • Prelude Capital Management's Kiniksa Pharmaceuticals position peaked at $292K in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.